Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | NEK2 | P51955 | 1/20 | 0.33 |
| ▸ | OTUD7B | Q6GQQ9 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13748033 | 0.81 | — | — | |
| SCHEMBL1700114 | 0.78 | KCNH2 (0.54) | CHRM2CHRM3KCNH2CRBNOTUD7B | |
| SCHEMBL15935920 | 0.77 | FGFR1 (0.38) | NEK2CYP1A2 | |
| SCHEMBL15935917 | 0.74 | KCNH2 (0.37) | KCNH2SIGMAR1CYP3A4MAPK1ALOX15 | |
| SCHEMBL15935945 | 0.72 | KCNH2 (0.38) | CHRM2CHRM3KCNH2CRBNDDB1 | |
| SCHEMBL15935940 | 0.72 | KCNH2 (0.38) | CHRM2CHRM3KCNH2CRBNDDB1 | |
| SCHEMBL800500 | 0.68 | CRBN (0.46) | CHRM2CHRM3CRBNDDB1NEK2 | |
| SCHEMBL13314948 | 0.68 | PLD1 (0.49) | CRBNDDB1OTUD7BHTR2AHTR2C | |
| SCHEMBL29388502 | 0.64 | MAP3K11 (0.39) | — | |
| SCHEMBL13342752 | 0.64 | KCNH2 (0.52) | CHRM2KCNH2CRBNOTUD7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796260-B2 | Imidazobenzazepine CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130245009-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| EP-2205599-B1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245009-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, BDKRB2 | CHRM2 166/4885CHRM3 219/4885KCNH2 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.